Carl is Professor of Pharmacy Practice, Medicine Use and Safety. He has a significant portfolio of research in optimising pharmacotherapy via pharmacokinetic/pharmacodynamic modelling techniques to improve patient outcomes. His research interests include population pharmacokinetic and pharmacodynamic modelling, monitoring and bayesian optimisation of dosing of antibacterial agents (especially aminoglycosides), optimisation of dosing in renal dysfunction, pharmacokinetics and dosing in obesity, drugs in breast milk and quality use of medicines.

Dr Jessica R. Tait is a Postdoctoral Research Fellow at the Monash-Moderna Quantitative Pharmacology Accelerator, based at Monash University in Parkville, Australia. Her research supports the development of mRNA-based vaccines and therapeutics through quantitative pharmacology, including pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetics modelling approaches. She completed her PhD in 2023 under the supervision of Associate Professor Cornelia Landersdorfer, with her thesis titled ‘Dynamic infection models, metabolomics and mechanism-based modelling to investigate pharmacodynamic challenges of Pseudomonas aeruginosa’. Dr Tait has co-authored over 15 peer-reviewed publications in leading journals and has presented numerous posters and oral presentations at premier pharmacology and anti-infective conferences.

Jia Li is a PhD candidate at the Centre for Medicine Use and Safety, Monash University. Her research focuses on model-informed drug development of anakinra in preterm neonates, including population pharmacokinetic (PPK), physiologically based pharmacokinetic (PBPK), and pharmacokinetic/ pharmacodynamic (PPK/PD) modelling approaches. Her work integrates the unique physiological characteristics of premature neonates to optimize dosing strategies and support clinical development. Jia holds a Bachelor’s degree in Pharmacy and a Master’s degree in Medicinal Chemistry. She has diverse experience across academia and the pharmaceutical industry, including roles as a manager coordinating preclinical and clinical studies in autoimmunology and oncology, and a researcher investigating the pathogenesis of neurodegenerative diseases.

Kenneth Brouwer is Vice President, ADME Tox Research at BioIVT. A pharmacologist by training, Dr. Brouwer has led in vitro ADME programs at GSK and at PPD. He later led development of B-CLEAR technology, a method to quantitate hepato-biliary excretion. He was a founder of Qualyst Transporter Solutions, where he expanded applications of B-CLEAR technology and developed assays that integrate uptake, efflux, and regulatory function of cells. In 2017, BioIVT acquired Qualyst, and Dr. Brouwer now helps biopharmaceutical clients design and implement in vitro ADME research programs to achieve their drug R&D and regulatory submission objectives.